Life Sciences
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The company said the latest round brings its total raise to $47 million.
The tool uses information about pain level, condition and current medication regimen to find an effective dose of opioids.
Also: Pediatric sleep app Huckleberry raises $12.5 million, and illumigyn, maker of a platform for remote gynecological imaging, brings in $33 million.
The POGO system was first cleared by the FDA in 2016.
The effort will be focused on using nocturnal scratch as an endpoint for atopic dermatitis.
The study will focus on Type 2 diabetes patients.
The study found only 46% of patients eligible for prophylactic low-dose aspirin due to high-risk factors for preeclampsia had gotten a provider recommendation by 16 weeks gestation.
The tool is aimed at helping people make informed decisions around vaccinations.
It has set up a new entity offering preventive healthcare solutions.